EcoDrugPlus

Phosphodiesterase 9a

Ensembl ID : ENSOTSG00005033297
Gene Symbol: PDE9A
1 Cross references
179 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSOTSG00005018685
Gene Symbol: PDE9A
1 Cross references
179 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSOTSG00005026031
Gene Symbol: PIK3R2
1 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSOTSG00005031830
Gene Symbol: PIK3R2
3 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOTSG00005019661
Gene Symbol: PIK3R5
3 Cross references
193 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOTSG00005023037
Gene Symbol: PIK3R5
3 Cross references
194 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOTSG00005038359
Gene Symbol: PIK3R5
3 Cross references
178 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOTSG00005026546
Gene Symbol: PIK3R5
3 Cross references
178 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSOTSG00005013198
Gene Symbol: PIK3R1
1 Cross references
196 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSOTSG00005010300
Gene Symbol: PIK3R1
1 Cross references
196 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSOTSG00005031258
Gene Symbol: PIK3R2
1 Cross references
183 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSOTSG00005047743
Gene Symbol: PLA2G10
1 Cross references
225 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).